August 13, 2025 — Dogwood Therapeutics Inc. (Nasdaq: DWTX) announced its second quarter financial results, reporting $13.4 million in cash, providing operational runway through Q1 2026. The company is developing new medicines to treat pain and fatigue-related disorders. Enrollment has reached 52 patients in the Halneuron® Phase 2b Trial, with interim data expected in Q4 2025.
The company’s proprietary pipeline includes Halneuron®, in Phase 2b development as a non-opioid NaV 1.7 inhibitor, and IMC-1 (famciclovir + celecoxib), ready for Phase 3 development as a combination antiviral treatment for Fibromyalgia. IMC-2 (valacyclovir + celecoxib) is in Phase 2a development as a combination antiviral treatment for Long-COVID.
Research and development expenses for the second quarter of 2025 were $2.5 million, compared to $0.3 million for the second quarter of 2024. General and administrative expenses for the second quarter of 2025 were $1.3 million, compared to $0.7 million for the second quarter of 2024. Net loss attributable to common stockholders for the second quarter of 2025 was $3.8 million, or $1.99 basic and diluted net loss per share, compared to a net loss attributable to common stockholders of $1.0 million, or $1.15 basic and diluted net loss per share, for the second quarter of 2024.
Greg Duncan, Chief Executive Officer of Dogwood Therapeutics.
Michael Gendreau, MD, PhD, Chief Medical Officer of Dogwood Therapeutics.
